JCR Pharmaceuticals
Biosimilar developer, Japan. 3 development products across 3 molecules: agalsidase beta, darbepoetin alfa, epoetin alfa and zeta.
About JCR Pharmaceuticals
JCR, based in Kobe, has three biosimilars approved in Japan and none elsewhere: epoetin in 2010, the second biosimilar approved in Japan; darbepoetin in 2019; and agalsidase beta in 2018, the only enzyme replacement biosimilar approved anywhere in the world.
Portfolio by market
| Molecule | Product | FDA | EMA | MHRA | PMDA | HC | CDSCO | EDE | Markets |
|---|---|---|---|---|---|---|---|---|---|
| Agalsidase beta | Agalsidase Beta BS JCR | · | · | · | Sep 2018 | · | · | · | 1/7 |
| Darbepoetin alfa | Darbepoetin Alfa BS JCR | · | · | · | Sep 2019 | · | · | · | 1/7 |
| Epoetin alfa and zeta | Epoetin Alfa BS JCR | · | · | · | Jan 2010 | · | · | · | 1/7 |
Month shown is the first approval or registration of that product in that market.
Companies on the same molecules
Developers whose portfolios overlap most with JCR Pharmaceuticals, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.
Chronology
- PMDAJan 2010Epoetin Alfa BS [JCR], epoetin alfa and zeta
- PMDASep 2018Agalsidase Beta BS [JCR], agalsidase beta
- PMDASep 2019Darbepoetin Alfa BS [JCR], darbepoetin alfa
Compare JCR Pharmaceuticals with other developers on the comparison page.
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant